PharmaFocus Today – Page 7 – media

China’s first innovative drug prescription based on precise postoperative assessment for thyroid cancer

On March 11, China’s first innovative drug　　for precise postoperative assessment of differentiated thyroid cancer was launched.Human thyroid-stimulating hormone beta (Zesuning) for injection at the First Affiliated Hospital of Zhejiang University School of MedicineThe first prescription was issued by Jiangsu Provincial People’s Hospital . Thyroid cancer is one of the fastest-growing solid tumors in recent years. Differentiated thyroid cancers, such as papillary carcinoma and follicular carcinoma, account for over 90% of cases. These tumors generally have a good prognosis, with a 10-year survival rate exceeding 90%. However, a high survival rate does not mean “no management is needed.” Studies show that approximately 10%-30% of patients still face the risk of recurrence or metastasis during postoperative follow-up. Therefore, regular and standardized postoperative follow-up to monitor for residual lesions or signs of recurrence is crucial for improving the long-term quality of life for these patients. For patients who have undergone total resection of ...
- Source: drugdu
- 64
- March 13, 2026
The launch meeting for the research project on innovative chemical drugs for Alzheimer’s disease was held.

On the afternoon of March 12, an innovative drug led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, was launched.The launch meeting for the National Science and Technology Major Project on Drug Development, ” Research on Innovative Chemical Drugs for Anti-Alzheimer’s Disease Targeting New Mechanisms,” was held in Shanghai. This meeting was conducted strictly in accordance with the special project management standards, systematically deploying the project’s overall objectives, technical roadmap planning, task allocation, clinical research layout, and funding management throughout the entire process. (Wanbangde)(002082) The wholly-owned subsidiary Wanbangde Pharmaceutical Group, together with the project lead unit, cooperating research institutions and industry experts, gathered together to discuss the details of the project implementation and build consensus on research and development. Alzheimer’s disease is the most common type of dementia in clinical practice and also the most prevalent neurodegenerative disease. Its main manifestations include progressive decline in memory, judgment, ...
- Source: drugdu
- 68
- March 13, 2026
Announcement Regarding the Inclusion of its Innovative Drug HSK31679 Tablets in the Breakthrough Therapy Program

March 12 – Harscon Pharmaceutical…The company announced that on March 12, 2026, it learned that HSK31679 tablets were officially included in the “Breakthrough Therapy List” by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, making it the first THR-β agonist to be included in the Breakthrough Therapy List in China. Currently, no drugs are approved in China for the treatment of MASH (non-alcoholic steatohepatitis). The inclusion of HSK31679 tablets in the “Breakthrough Therapy List” will greatly promote the research and development of new drugs in this field and bring new hope for the treatment of MASH patients in my country. https://finance.eastmoney.com/a/202603123670377648.html
- Source: drugdu
- 66
- March 13, 2026
SHR-9803 for Injection Approved for Clinical Trials

On March 11, Hengrui Medicine (600276/01276) issued an announcement stating that the company recently received the “Drug Clinical Trial Approval Notice” for SHR-9803 for injection issued by the National Medical Products Administration, and will conduct clinical trials in the near future. This drug is a Class 1 therapeutic biological product.It can activate anti-tumor immune activity, specifically bind to and eliminate regulatory T cells within tumors, while reducing the impact on peripheral Tregs, aiming to improve the safety and efficacy of tumor treatment. To date, the cumulative R&D investment in SHR-9803 injection-related projects is approximately RMB 18.3 million (unaudited). In the first three quarters of 2025, Hengrui Medicine achieved revenue of RMB 23.188 billion and net profit attributable to the parent company of RMB 5.751 billion. https://finance.eastmoney.com/a/202603113668880571.html
- Source: drugdu
- 72
- March 12, 2026
Invests 5 million yuan to participate in the establishment of an investment fund to expand into the biopharmaceutical field

Lumay Pharmaceutical(300006) announced on March 12 that the company recently signed an agreement with Xi’an Wojie Private Equity Fund Management Co., Ltd. and Sansure Biotech.Several institutions, including a technology company, signed a partnership agreement to jointly establish Guangzhou Shengquan Baijie Venture Capital Fund Partnership (Limited Partnership). The fund aims to raise a total of RMB 150 million, of which the company, as a limited partner, will contribute RMB 5 million from its own funds, representing a 3.33% stake. The investment fund primarily invests in innovative biopharmaceuticals and medical devices .In vitro diagnosticsIn the life and health sectors, investments in these industries shall not be less than 60% of the fund’s total paid-in capital. The fund focuses on investing in Guangzhou’s strategic emerging industries and future industries, and has established a fund for seed companies in Guangzhou.Investment ratio requirements for early-stage and angel-stage projects. According to the announcement, the company’s investment ...
- Source: drugdu
- 62
- March 12, 2026
Huadong Medicine’s clinical trial application for injectable HDM2024 drug has been approved by the US FDA

March 11, Huadong Medicine…(000963) issued an announcement stating that its wholly-owned subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd. (hereinafter referred to as “Sino-American East China”), received a notification from the U.S. Food and Drug Administration (hereinafter referred to as “FDA”) that the clinical trial application for injectable HDM2024 submitted by Sino-American East China has been approved by the U.S. FDA and can be carried out in the United States for Phase I clinical trials, with the indication being advanced solid tumors. Huadong Medicine stated that the approval of the US clinical trial of injectable HDM2024 is another important step in the product’s development process and will further enhance the company’s core competitiveness in the field of oncology treatment. https://finance.eastmoney.com/a/202603113668988846.html
- Source: drugdu
- 67
- March 12, 2026
Its subsidiary’s Class 1 innovative drug TQB3205 has been approved for clinical trials, intended for the treatment of advanced malignant tumors.

On March 11, China Biopharmaceutical (01177) issued an announcement stating that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has independently developed a Class 1 innovative drug.TQB3205 has received clinical trial approval from the China National Medical Products Administration and is intended for the treatment of advanced malignant tumors. TQB3205 is an oral pan-KRAS inhibitor that effectively inhibits the proliferation of various KRAS-mutated tumor cells. The company will accelerate the clinical development of TQB3205, aiming to overcome existing treatment limitations and bring new treatment options to a wider range of patients with KRAS-mutated advanced malignancies. https://finance.eastmoney.com/a/202603113668972521.html
- Source: drugdu
- 65
- March 12, 2026
Novogene® has been approved, making its global debut in China!

Recently, the National Medical Products Administration (NMPA) officially approved the marketing application of Novogene® (insulin smegglutide injection) in China. Novogene® is the world ‘s first and currently only approved basal insulin/glucagon-like peptide-1 receptor agonist (GLP-1RA) weekly formulation. It consists of the world’s first insulin weekly formulation, insulin smegglutide, and the globally widely used GLP-1RA weekly formulation, smegglutide[1]. It is suitable for adult patients with type 2 diabetes whose blood glucose control is poor after basal insulin or GLP-1RA treatment, and is used in combination with oral hypoglycemic drugs on the basis of diet and exercise [2] . Multidimensional blood glucose management and Patient treatment adherence remains high in type 2 diabetes. Key challenges in treatment ﹀ There are approximately 589 million adults with diabetes worldwide, of whom more than 90% have type 2 diabetes [3] . Insulin therapy is the cornerstone of diabetes management [4] , but in clinical practice, ...
- Source: drugdu
- 82
- March 10, 2026
CSPC indacaterol mometasone inhalation powder has been approved for clinical trials in China.

On March 5, CSPC Pharmaceutical Group (1093.HK) announced that…The indacaterol mometasone inhalation powder developed by our Group (hereinafter referred to as “the Product”) has been approved by the National Medical Products Administration and can be used for clinical trials in China.This product is used for maintenance treatment of asthma in adults and adolescents aged 12 years and older. Indacaterol is a long-acting β2-adrenergic agonist (LABA) with smooth muscle relaxant and bronchodilator effects. Mometasone furoate is an inhaled corticosteroid (ICS) with local anti-inflammatory effects. Indacaterol-Mometasone Inhalation Powder is the first once-daily inhaled ICS-LABA dual-combination inhaled formulation included in the National Medical Insurance Catalog (2022 Edition), providing asthma patients with a more efficient and convenient treatment option. The approval of the clinical trial for this product is another important achievement of the Group’s high-end innovative inhalation technology platform, laying a solid foundation for the development of subsequent inhalation formulations in the pipeline. ...
- Source: drugdu
- 73
- March 10, 2026
Hengrui Medicine subsidiary’s HRS9531 injection has been approved for clinical use in chronic kidney disease

On March 9, Hengrui Medicine (600276/01276) issued an announcement stating that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for HRS9531 injection issued by the National Medical Products Administration, and will conduct clinical trials in the near future. The application for this drug was for clinical trials, with application numbers CXHL2501355 and CXHL2501356. The approval conclusion indicated that the application met the relevant requirements for drug registration and approved the commencement of clinical trials for chronic kidney disease. HRS9531 injection is a globally proprietary intellectual property.This novel dual agonist targeting both gastric inhibitory peptide receptor and glucagon-like peptide-1 receptor has the effects of regulating glucose and lipid metabolism, suppressing appetite, and enhancing insulin sensitivity. To date, the cumulative R&D investment in HRS9531-related projects is approximately RMB 632 million (unaudited). The company reminds investors that the drug development and market launch process is lengthy ...
- Source: drugdu
- 77
- March 10, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.